These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11238542)

  • 1. Raloxifene affects brain activation patterns in postmenopausal women during visual encoding.
    Neele SJ; Rombouts SA; Bierlaagh MA; Barkhof F; Scheltens P; Netelenbos JC
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1422-4. PubMed ID: 11238542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior.
    Goekoop R; Duschek EJ; Knol DL; Barkhof F; Netelenbos C; Scheltens P; Rombouts SA
    Neuroimage; 2005 Mar; 25(1):63-75. PubMed ID: 15734344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males.
    Goekoop R; Barkhof F; Duschek EJ; Netelenbos C; Knol DL; Scheltens P; Rombouts SA
    Neuropsychopharmacology; 2006 Jul; 31(7):1508-18. PubMed ID: 16292319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
    Huerta-Ramos E; Iniesta R; Ochoa S; Cobo J; Miquel E; Roca M; Serrano-Blanco A; Teba F; Usall J
    Eur Neuropsychopharmacol; 2014 Feb; 24(2):223-31. PubMed ID: 24342775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.
    Vogelvang TE; Mijatovic V; van der Mooren MJ; Pinsdorf U; von Bergmann K; Netelenbos JC; Lütjohann D
    Maturitas; 2005 Apr; 50(4):312-20. PubMed ID: 15780532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks.
    Shaywitz SE; Shaywitz BA; Pugh KR; Fulbright RK; Skudlarski P; Mencl WE; Constable RT; Naftolin F; Palter SF; Marchione KE; Katz L; Shankweiler DP; Fletcher JM; Lacadie C; Keltz M; Gore JC
    JAMA; 1999 Apr; 281(13):1197-202. PubMed ID: 10199429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.
    Usall J; Huerta-Ramos E; Labad J; Cobo J; Núñez C; Creus M; Parés GG; Cuadras D; Franco J; Miquel E; Reyes JC; Roca M;
    Schizophr Bull; 2016 Mar; 42(2):309-17. PubMed ID: 26591005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
    Usall J; Huerta-Ramos E; Iniesta R; Cobo J; Araya S; Roca M; Serrano-Blanco A; Teba F; Ochoa S
    J Clin Psychiatry; 2011 Nov; 72(11):1552-7. PubMed ID: 21903021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia.
    Kulkarni J; Gurvich C; Lee SJ; Gilbert H; Gavrilidis E; de Castella A; Berk M; Dodd S; Fitzgerald PB; Davis SR
    Psychoneuroendocrinology; 2010 Sep; 35(8):1142-7. PubMed ID: 20171784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive selective estrogen receptor modulator increases neural activity in the hippocampus and inferior frontal gyrus during emotional face recognition in schizophrenia.
    Ji E; Weickert CS; Lenroot R; Kindler J; Skilleter AJ; Vercammen A; White C; Gur RE; Weickert TW
    Transl Psychiatry; 2016 May; 6(5):e795. PubMed ID: 27138794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive function in postmenopausal women treated with raloxifene.
    Yaffe K; Krueger K; Sarkar S; Grady D; Barrett-Connor E; Cox DA; Nickelsen T;
    N Engl J Med; 2001 Apr; 344(16):1207-13. PubMed ID: 11309635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene improves verbal memory in late postmenopausal women: a randomized, double-blind, placebo-controlled trial.
    Jacobsen DE; Samson MM; Emmelot-Vonk MH; Verhaar HJ
    Menopause; 2010 Mar; 17(2):309-14. PubMed ID: 19918203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
    Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL
    Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of raloxifene on sexual function in postmenopausal women.
    Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
    Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
    Vogelvang TE; Leurs JR; van der Mooren MJ; Mijatovic V; Hendriks DF; Neele SJ; Netelenbos JC; Kenemans P
    Menopause; 2004; 11(1):110-5. PubMed ID: 14716191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
    Vogelvang TE; Mijatovic V; Kenemans P; Emeis JJ; Heijst JA; van der Mooren MJ
    Am J Obstet Gynecol; 2005 Oct; 193(4):1384-94. PubMed ID: 16202731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women.
    Ott SM; Oleksik A; Lu Y; Harper K; Lips P
    J Bone Miner Res; 2002 Feb; 17(2):341-8. PubMed ID: 11811565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
    Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
    Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.